Procognia announced the introduction of the first human kinase protein function array for use in compound profiling and other drug screening applications in September 2005
Rachel Fallon, VP research and development and operations, presented the novel array technology during a tutorial session as part of the SBS (Society of Biomolecular Screening) conference programme.
Procognia presented a competition assay in which potential small molecule inhibitors are tested for binding to kinases in the presence of fluorescently labelled universal binder.
The tutorial demonstrated selectivity data and IC50 values obtained against an array of human kinases.
It will also show that this assay format can be applied to compound profiling against hundreds of kinases with same-day results.
The new human kinase array is the latest addition to Procognia's expanding portfolio of functional protein arrays.
These arrays and assays are developed on a custom design basis directly with Procognia.
Life science catalogue products for themed arrays of proteins of interest will also be available via an exclusive marketing agreement with Sigma-Aldrich.
Whatever the customer requirement, Procognia's protein function arrays can increase the productivity of researchers' drug discovery and development programmes by delivering fast and reproducible results.
Using proprietary tagging technology which ensures arrayed proteins are folded and therefore functional, hundreds of proteins can be assayed in hours.
As well as applying the array technology for protein:small molecule interaction, Procognia's functional protein arrays are also used for other applications such as protein:protein interactions and kinase substrate identification.
Ron Long, CEO and chairman of Procognia, said, "We are developing platforms at Procognia designed to improve productivity in drug discovery, development and manufacture.
"Our aim is to help develop a more comprehensive understanding of proteins as targets and as therapeutics and today we are working on a programme to array the proteome in druggable classes."
